Chronic obstructive pulmonary disease (COPD) is a progressive and severe respiratory disease featuring airway obstruction and recurrent exacerbations, driven by a complex network of inflammatory processes. In their Review, Agusti and co-authors appraise drugs in development for COPD including recently approved antibodies targeting IL-4 and IL-5 signalling. They discuss opportunities to improve the success of future interventions, including considerations to optimize clinical trial design.
- Alvar Agusti
- Dave Singh
- Rosa Faner
